Navigation Links
European Dental Biomaterial Revenues Will Grow To Over $375 Million In 2021, In Line With Rising Dental Implant Placements
Date:4/10/2013

TORONTO, April 10, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European market for dental biomaterials will see strong expansion through 2021 as their use increases alongside dental implant procedures, which often incorporate dental biomaterials. As the European population ages and awareness of available treatments grows, dental implants will see strong adoption, driving the uptake of biomaterials.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

The bone graft substitute (BGS) segment continues to generate the most revenue in the European dental biomaterial market because these products are used fairly frequently in dental implant procedures. Within the BGS market, competitors have been primarily focusing on the synthetic market in recent years because there is still room for improvement for these products.

"Despite a number of product launches in the synthetic BGS market, Geistlich is still the clear market leader with its popular Bio-Oss xenograft product," said MRG Analyst Kristina Vidug . "Geistlich has high loyalty among key opinion leaders in the dentistry industry and its product is supported by long-term, positive clinical results. Geistlich's strong position in the BGS and dental membrane markets have allowed the company to lead the dental biomaterial market overall."

In the tissue regeneration product market, Straumann continues to be the only competitor. Although BioMimetic Therapeutics' GEM 21S received CE marking early 2012, it was subsequently revoked for reevaluation at the request of Luitpold Pharmaceuticals. The product is, however, anticipated to have CE marking reinstated in the future, creating competition for Straumann.

One of the main factors hindering the European dental biomaterial market will be the high price of dental procedures. Given economic concerns in Europe, some patients are postponing or cancelling dental treatments, particularly expensive surgeries. This will be most notable in Italy and Spain, where market growth will be slow over the next few years. Sweden, on the other hand, will experience the fastest growth of the countries covered in this report because dental implant procedures are partially reimbursed.

Millennium Research Group's European Markets for Dental Biomaterials 2013 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for bone graft substitutes, dental membranes and tissue regeneration products in France, Germany, Italy, Spain, Sweden, Switzerland and the United Kingdom.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net

 


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Western European Endoscopic Devices Market to Benefit from Increase in Minimally Invasive Surgeries, Says Frost & Sullivan
2. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
3. SonaCare Medical Successfully Launches New Products at European Association of Urology (EAU)
4. N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
5. Chimerixs Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantations Annual Meeting
6. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
7. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
8. Genalyte Announces CE Mark For Maverick(TM) Detection System And Signs On First European Distributors
9. European Commission Designates MST-188 As An Orphan Medicinal Product
10. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
11. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017   Pulmatrix, Inc . (NASDAQ: ... to address serious pulmonary diseases, today announced that it has ... cystic fibrosis and asthma to its Scientific Advisory Board ... Richard B. Moss , MD, former chief of ... the Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 On ... the NASDAQ Composite closed the trading session up 0.19%; ... the S&P 500 was down 0.08%. US markets made ... finishing the day in green. Pre-market today, Stock-Callers.com reviews ... Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx ...
(Date:3/27/2017)... March 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today ... Paul M. Bisaro as Impax,s President and Chief ... effective March 27, 2017. Mr. Bisaro will succeed ... President and Chief Executive Officer since December of 2016. ... branded pharmaceutical experience, Mr. Bisaro, 56, is an accomplished ...
Breaking Medicine Technology:
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... restoration treatment, is proud to announce a new blog post about women’s hair loss. ... women suffer from hair loss as they age. Menopause or genetics can be two ...
(Date:3/28/2017)... Louis, MO (PRWEB) , ... March 28, 2017 ... ... levels of job satisfaction in their profession as their value increases in the ... company that provides resources such as job boards, career fairs, and candidate leads ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to experience the benefits ... now have them placed by Dr. Manju Kejriwal, with or without a referral. Dr. ... increase the accuracy of each dental implant placement. The i-CAT CBCT system captures the ...
(Date:3/27/2017)... ... March 27, 2017 , ... This ... OSEHRA popHealth Community in 2014. It is the culmination of collaborative ... Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded the ONC certification ...
Breaking Medicine News(10 mins):